Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Nebulizer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    41 result(s) found for: Nebulizer. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2013-002783-12 Sponsor Protocol Number: BAYq6256/16483 Start Date*: 2014-01-07
    Sponsor Name:Bayer HealthCare AG
    Full Title: A multi-center, open-label, randomized cross-over study to compare the acute tolerability and pharmacokinetics of BAY Q 6256 (iloprost; Ventavis) inhalation using the I-Neb nebulizer and the FOX ne...
    Medical condition: Patients with Pulmonary arterial hypertension, WHO class III, who have been on therpay with Ventavis 10 for at least 4 weeks
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004855 10036727 Primary pulmonary hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2013-004488-30 Sponsor Protocol Number: TAPAS-PK-2014 Start Date*: 2014-01-31
    Sponsor Name:Haga Hospital
    Full Title: Targeting Antibiotics to Pseudomonas Aeruginosa in Small airways (TAPAS) study in patients with cystic fibrosis: pharmacokinetics (PK)
    Medical condition: Cystic fibrosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023981-27 Sponsor Protocol Number: Acti-SCIPE-001 Start Date*: 2011-03-08
    Sponsor Name:Activaero GmbH
    Full Title: An Open-Label Randomized Pilot Trial to Evaluate Tolerability, Safety and Applicability of AKITA Inhaled Budesonide Suspension in Children aged 3-11 years with Mild to Moderate Asthma
    Medical condition: Allergic or non-allergic mild to moderate asthma in children aged three to eleven years. Affected children need to suffer from mild to moderate asthma according to ATS definition at least for 6 mon...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10003561 Asthma, unspecified LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-001263-85 Sponsor Protocol Number: SAV006-05 Start Date*: 2021-07-19
    Sponsor Name:Savara ApS
    Full Title: A randomized, double-blind, placebo-controlled clinical trial of once-daily inhaled molgramostim nebulizer solution in adult subjects with autoimmune pulmonary alveolar proteinosis (aPAP).
    Medical condition: Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10037316 Pulmonary alveolar proteinosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) IE (Ongoing) DE (Ongoing) PL (Ongoing) BE (Ongoing) IT (Ongoing) ES (Ongoing) PT (Ongoing) RO (Ongoing) GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004794-33 Sponsor Protocol Number: PA101B-UP-02 Start Date*: 2016-03-25
    Sponsor Name:Patara Pharma, LLC
    Full Title: Treatment of Uremic Pruritus with Inhaled PA101B in Patients with End-Stage Renal Disease Requiring Hemodialysis
    Medical condition: Uremic Pruritus in patients with end-stage renal disease requiring hemodialysis
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004858 10060884 Uremic pruritus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003537-99 Sponsor Protocol Number: ML28249 Start Date*: 2016-07-05
    Sponsor Name:F. Hoffmann-La Roche AG
    Full Title: A PHASE IV MULTICENTER, RANDOMIZED, OPEN LABEL, TWO-PERIOD CROSSOVER STUDY IN PATIENTS WITH CYSTIC FIBROSIS TO EVALUATE THE COMPARABLE EFFICACY AND SAFETY OF PULMOZYME® DELIVERED BY THE ERAPID™ NEB...
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-001541-40 Sponsor Protocol Number: Pro12/15 Start Date*: 2012-08-20
    Sponsor Name:Vu University Medical Center
    Full Title: Effect of Carbon Dioxide Enriched Ambient Air on Pharmacokinetics and Deposition In Bronchiectasis Patients Using Tobramycin Inhalation: A proof of concept study.
    Medical condition: Bronchiectasis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10006446 Bronchiectasis NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-000473-12 Sponsor Protocol Number: ULT01 Start Date*: 2015-10-12
    Sponsor Name:UMCG
    Full Title: The effectiveness of single dose Ultibro Breezhaler (indacaterol/glycopyrronium) by sd-DPI versus ipratropium/salbutamol by nebulizer in improving FEV1 and dyspnea during stable state of COPD
    Medical condition: COPD, chronic obstructive pulmonary disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2007-000959-33 Sponsor Protocol Number: CTP G007.04 Start Date*: 2007-08-16
    Sponsor Name:PARI GmbH
    Full Title: Randomized, open labelled, cross over deposition study of Tobramycin 100 PARI nebulized with eFlow® versus TOBI® nebulized with PARI LC PLUS® in subjects with CF
    Medical condition: Cystic Fibrosis with Pseudomonas aeruginosa infection
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002465-30 Sponsor Protocol Number: EE-01bude2014 Start Date*: Information not available in EudraCT
    Sponsor Name:Dip. Pediatria UOC Gastroenterologia ed Epatologia Pediatrica
    Full Title: Spontaneous study on the efficacy and safety of an oral viscous suspension of budesonide administered to children affected by eosinophilic esophagitis.
    Medical condition: Eosinophilic Esophagitis
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-010821-38 Sponsor Protocol Number: EP-101-01 Start Date*: 2009-05-07
    Sponsor Name:Elevation Pharmaceuticals, Inc
    Full Title: Single-Dose, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Bronchodilatory Effects of Glycopyrrolate Inhalation Solution (GIS) Using a High Efficiency Nebulizer in ...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-014640-11 Sponsor Protocol Number: Acti-AICS-001 Start Date*: 2010-01-26
    Sponsor Name:Activaero GmbH
    Full Title: A Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate Tolerability, Safety and Efficacy of AKITA Inhaled Steroid Suspension for Inhalation (AICS) in Subjects with Asthma Requiring Chroni...
    Medical condition: Subjects with Asthma Requiring Chronic Oral Corticosteroid Treatment
    Disease: Version SOC Term Classification Code Term Level
    12.0 10003555 Asthma bronchial LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-002749-42 Sponsor Protocol Number: GS-US-205-1850 Start Date*: 2017-09-18
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: Randomized, Double-Blind, Phase 3B Trial to Evaluate the Safety and Efficacy of 2 Treatment Regimens of Aztreonam 75 mg Powder and Solvent for Nebulizer Solution / Aztreonam for Inhalation Solution...
    Medical condition: Cystic fibrosis and new onset lower respiratory tract culture positive for Pseudomonas aeruginosa
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10068288 Cystic fibrosis pulmonary exacerbation LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) IE (Completed) AT (Completed) FR (Completed) DE (Completed) ES (Completed) NL (Completed) IT (Completed) GR (Completed) DK (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-001401-41 Sponsor Protocol Number: TAPAS-2014 Start Date*: 2014-07-29
    Sponsor Name:
    Full Title: Targeting Antibiotics to Pseudomonas Aeruginosa in Small airways (TAPAS) study in patients with cystic fibrosis
    Medical condition: Cystic Fibrosis and chronic infection with Pseudomonas aeruginosa
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-000164-17 Sponsor Protocol Number: tobra nasal CF pilot Start Date*: 2008-08-13
    Sponsor Name:University of Jena
    Full Title: Nasale Inhalation von Tobramycin mit dem Pari Sinus-Vernebler bei Patienten mit Mukoviszidose und Pseudomonasnachweis im Nasen-Nasennebenhöhlenbereich. Nasal inhalation of tobramycin by the Pari ...
    Medical condition: subjects with cystic fibrosis and pseudomonas aeruginosa colonization in the upper airways
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-004959-50 Sponsor Protocol Number: Heliox-AP Start Date*: 2016-05-29
    Sponsor Name:S.E. Carburos Metálicos S.A. grupo Air Products
    Full Title: HELIOX-DRIVEN BETA2-AGONISTS NEBULIZATION FOR CHILDREN WITH MODERATE TO SEVERE ACUTE ASTHMA: A RANDOMIZED CONTROLLED TRIAL
    Medical condition: Moderate to severe exacerbations of asthma
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10064823 Asthmatic crisis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-001565-33 Sponsor Protocol Number: CTBM100C2403 Start Date*: 2013-06-21
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label, crossover, interventional Phase IV study to compare the ease of use of tobramycin inhalation powder with tobramycin inhalation solution and nebulized colistimethate for the treatment...
    Medical condition: Chronic lung infection with Pseudomonas aeruginosa in cystic fibrosis patients
    Disease: Version SOC Term Classification Code Term Level
    17.1 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    17.1 100000004862 10021860 Infection Pseudomonas aeruginosa LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2005-003772-37 Sponsor Protocol Number: CTBM100C2302 Start Date*: 2006-01-06
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Randomized, Open-label, Multicenter, Phase 3 Trial to Assess the Safety of Tobramycin Inhalation Powder Compared to TOBI® in Cystic Fibrosis Subjects
    Medical condition: Pulmonary pseudomonas aeruginosa infections in patients with cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    10011762
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed) IT (Completed) HU (Completed) GR (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2015-004870-14 Sponsor Protocol Number: LOC114220 Start Date*: 2016-08-03
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study to determine the efficacy and safety of nebulized fluticasone propionate 1mg twice daily compared with...
    Medical condition: Asthma
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-002696-18 Sponsor Protocol Number: SUN101-303 Start Date*: 2013-12-18
    Sponsor Name:Sunovion Respiratory Development Inc.
    Full Title: A Randomized, Open-Label, Active-Controlled, Parallel-Group, Multicenter, Long-Term Safety Trial of Treatment with Nebulized SUN-101 in Patients with COPD: GOLDEN-5 (Glycopyrrolate for Obstructive ...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    17.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 03:35:34 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA